MDI 403

Drug Profile

MDI 403

Latest Information Update: 26 Aug 2004

Price : $50

At a glance

  • Originator Molecular Design International
  • Class Antiacnes; Keratolytics; Retinoids
  • Mechanism of Action Retinoic acid metabolism modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Acne; Photodamage

Most Recent Events

  • 24 Aug 2004 Discontinued - Phase-I for Photodamage in USA (Topical)
  • 24 Aug 2004 Discontinued - Phase-II for Acne in USA (Topical)
  • 24 Aug 2004 Molecular Design International is now pursuing development of MDI 403 as a cosmetic product for fine line wrinkle reduction
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top